Minimal Residual Disease-Directed Therapy of Acute Promyelocytic Leukaemia

被引：0
作者：
Grimwade, David [1 ]
机构：
[1] Kings Coll London, Dept Med & Mol Genet, Sch Med, London, England
来源：
ANNALS OF HEMATOLOGY | 2013年 / 92卷
关键词：
TRANS-RETINOIC ACID; ANTHRACYCLINE-BASED CHEMOTHERAPY; STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; ACUTE MYELOID-LEUKEMIA; ARSENIC TRIOXIDE; FUSION GENE; REMISSION; STANDARDIZATION; SURVIVAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S41 / S44
页数：4
相关论文
共 24 条
  • [1] antamaria C, 2007, HAEMATOLOGICA, V92, P315
  • [2] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    Cheson, BD
    Bennett, JM
    Kopecky, KJ
    Büchner, T
    Willman, CL
    Estey, EH
    Schiffer, CA
    Döhner, H
    Tallman, MS
    Lister, TA
    LoCocco, F
    Willemze, R
    Biondi, A
    Hiddemann, W
    Larson, RA
    Löwenberg, B
    Sanz, MA
    Head, DR
    Ohno, R
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
  • [3] Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99):: benefit of an early intervention
    Esteve, J.
    Escoda, L.
    Martin, G.
    Rubio, V.
    Diaz-Mediavilla, J.
    Gonzalez, M.
    Rivas, C.
    Alvarez, C.
    San Miguel, J. D. Gonzalez
    Brunet, S.
    Tomas, J. F.
    Tormo, M.
    Sayas, M. J.
    Godoy, P. Sanchez
    Colomer, D.
    Bolufer, P.
    Sanz, M. A.
    [J]. LEUKEMIA, 2007, 21 (03) : 446 - 452
  • [4] Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Estey, E
    Garcia-Manero, G
    Ferrajoli, A
    Faderl, S
    Verstovsek, S
    Jones, D
    Kantarjian, H
    [J]. BLOOD, 2006, 107 (09) : 3469 - 3473
  • [5] Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
    Estey, EH
    Giles, FJ
    Kantarjian, H
    O'Brien, S
    Cortes, J
    Freireich, EJ
    Lopez-Berestein, G
    Keating, M
    [J]. BLOOD, 1999, 94 (07) : 2230 - 2235
  • [6] Development of minimal residual disease-directed therapy in acute myeloid leukemia
    Freeman, Sylvie D.
    Jovanovic, Jelena V.
    Grimwade, David
    [J]. SEMINARS IN ONCOLOGY, 2008, 35 (04) : 388 - 400
  • [7] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
    Gabert, J
    Beillard, E
    van der Velden, VHJ
    Bi, W
    Grimwade, D
    Pallisgaard, N
    Barbany, G
    Cazzaniga, G
    Cayuela, JM
    Cavé, H
    Pane, F
    Aerts, JLE
    De Micheli, D
    Thirion, X
    Pradel, V
    González, M
    Viehmann, S
    Malec, M
    Saglio, G
    van Dongen, JJM
    [J]. LEUKEMIA, 2003, 17 (12) : 2318 - 2357
  • [8] Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
    Ghavamzadeh, A
    Alimoghaddam, K
    Ghaffari, SH
    Rostami, S
    Jahani, M
    Hosseini, R
    Mossavi, A
    Baybordi, E
    Khodabadeh, A
    Iravani, M
    Bahar, B
    Mortazavi, Y
    Totonchi, M
    Aghdami, N
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (01) : 131 - 134
  • [9] The significance of minimal residual disease in patients with t(15;17)
    Grimwade, D
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 137 - 158
  • [10] Grimwade D, 1999, BLOOD, V94, p625A
123